CoChat

Una revisión de los avances en la terapéutica de la enfermedad de Alzheimer: estrategia frente a la proteína β-amiloide

Open access
Folch, J., Ettcheto, M., Petrov, D., Abad, S., Pedrós, I., Marin, M., Olloquequi, J., Camins, A. · 2018 · Neurología
Cited by 97

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

La enfermedad de Alzheimer (EA) es el principal trastorno neurodegenerativo que provoca una discapacidad intelectual total en los pacientes que la presentan. La elevada prevalencia a nivel mundial, así como la elevada carga socioeconómica que conlleva la EA para la sociedad en general, hace que sea considerada un importante problema de salud pública en este siglo xxi. En este trabajo se revisan los tratamientos actuales y en fase de desarrollo que actúan principalmente sobre la proteína β-amiloide. La hipótesis amiloidogénica propone que el péptido β-amiloide tiene un papel clave en esta enfermedad. Se han desarrollado varias estrategias farmacológicas diferentes con el objetivo de inhibir la formación de los péptidos β-amiloides, como son los inhibidores de β-secretasa y γ-secretasa. Además, se han desarrollado los tratamientos antiamiloide, que incluyen inmunoterapias pasivas y activas enfocadas a inhibir la agregación del péptido β-amiloide. Los avances en la identificación de las bases moleculares de la EA pueden servir como modelo para comprender las causas de esta enfermedad neurodegenerativa. Sin embargo, los ensayos clínicos más recientes en 2 ensayos de fase iii con solanezumab, un anticuerpo monoclonal humanizado que promueve el aclaramiento del β-amiloide en el cerebro, indican que este anticuerpo no muestra eficacia en pacientes con EA leve, sugiriendo que hay que replantearse esta hipótesis amiloidogénica de la EA. Alzheimer disease (AD) is a major neurodegenerative disorder which eventually results in total intellectual disability. The high global prevalence and the socioeconomic burden associated with the disease pose major challenges for public health in the 21st century. In this review we focus on both existing treatments and the therapies being developed, which principally target the β-amyloid protein. The amyloidogenic hypothesis proposes that β-amyloid plays a key role in AD. Several pharmacological approaches aim to reduce the formation of β-amyloid peptides by inhibiting the β-secretase and γ-secretase enzymes. In addition, both passive and active immunotherapies have been developed for the purpose of inhibiting β-amyloid peptide aggregation. Progress in identifying the molecular basis of AD may provide better models for understanding the causes of this neurodegenerative disease. The lack of efficacy of solanezumab (a humanised monoclonal antibody that promotes β-amyloid clearance in the brain), demonstrated by 2 recent Phase III clinical trials in patients with mild AD, suggests that the amyloidogenic hypothesis needs to be revised.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nrl.2015.03.012

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 50

  1. Thies, 2013, Alzheimer's Association. 2013 Alzheimer's disease facts and figures, Alzheimers Dement., 9, 208, 10.1016/j.jalz.2013.02.003 · DOI · Paper page
  2. Chiang, 2014, Emerging therapeutics for Alzheimer's disease, Annu Rev Pharmacol Toxicol., 54, 381, 10.1146/annurev-pharmtox-011613-135932 · DOI · Paper page
  3. Francis, 2005, A preclinical view of cholinesterase inhibitors in neuroprotection: Do they provide more than symptomatic benefits in Alzheimer's disease, Trends Pharmacol Sci., 26, 104, 10.1016/j.tips.2004.12.010 · DOI
  4. Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics, Science., 297, 353, 10.1126/science.1072994 · DOI · Paper page
  5. Castello, 2013, Rational heterodoxy: Cholesterol reformation of the amyloid doctrine, Ageing Res Rev, 12, 282, 10.1016/j.arr.2012.06.007 · DOI · Paper page
  6. Castello, 2014, On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis, Ageing Res Rev, 13, 10, 10.1016/j.arr.2013.10.001 · DOI
  7. Ferreira, 2014, Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease, Alzheimers Dement., 10, S76, 10.1016/j.jalz.2013.12.010 · DOI · Paper page
  8. De Felice, 2014, Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease, Diabetes., 63, 2262, 10.2337/db13-1954 · DOI · Paper page
  9. De Felice, 2013, Alzheimer's disease and insulin resistance: Translating basic science into clinical applications, J Clin Invest., 123, 531, 10.1172/JCI64595 · DOI · Paper page
  10. Vassar, 2011, The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease, Alzheimer's Res Ther., 3, 20, 10.1186/alzrt82 · DOI · Paper page
  11. Menting, 2014, β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease, Front Aging Neurosci., 6, 165, 10.3389/fnagi.2014.00165 · DOI · Paper page
  12. Yan, 2014, Targeting the β secretase BACE1 for Alzheimer's disease therapy, Lancet Neurol., 13, 319, 10.1016/S1474-4422(13)70276-X · DOI · Paper page
  13. Chiang, 2014, Emerging therapeutics for Alzheimer's disease, Annu Rev Pharmacol Toxicol., 54, 381, 10.1146/annurev-pharmtox-011613-135932 · DOI · Paper page
  14. Imbimbo, 2011, γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes, Curr Top Med Chem., 11, 1555, 10.2174/156802611795860942 · DOI · Paper page
  15. Wolfe, 2012, γ-secretase as a target for Alzheimer's disease, Adv Pharmacol., 64, 127, 10.1016/B978-0-12-394816-8.00004-0 · DOI
  16. Coric, 2012, Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease, Arch Neurol., 69, 1430, 10.1001/archneurol.2012.2194 · DOI · Paper page
  17. Dockens, 2012, A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects, Clin Pharmacokinet., 51, 681, 10.1007/s40262-012-0005-x · DOI
  18. Tong, 2012, Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men, Clin Drug Investig., 32, 761, 10.1007/s40261-012-0006-4 · DOI
  19. Jaturapatporn, 2012, Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease, Cochrane Database Syst Rev., 2, CD006378
  20. Ross, 2013, CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: A 12-week, double-blind, placebo-controlled study, Curr Alzheimer Res., 10, 742, 10.2174/13892037113149990144 · DOI · Paper page
  21. Imbimbo, 2013, Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects, Alzheimer Dis Assoc Disord., 27, 278, 10.1097/WAD.0b013e3182622ace · DOI
  22. Ronsisvalle, 2014, CHF5074 protects SH-SY5Y human neuronal-like cells from amyloidbeta 25-35 and tumor necrosis factor related apoptosis inducing ligand toxicity in vitro, Curr Alzheimer Res., 11, 714, 10.2174/1567205011666140618104430 · DOI
  23. Lee, 2014, Ice plant (Mesembryanthemum crystallinum) improves hyperglycaemia and memory impairments in a Wistar rat model of streptozotocin-induced diabetes, J Sci Food Agric., 94, 2266, 10.1002/jsfa.6552 · DOI
  24. Pitt, 2013, Protection against the synaptic targeting and toxicity of Alzheimer's-associated Aβ oligomers by insulin mimetic chiro-inositols, FASEB J., 27, 199, 10.1096/fj.12-211896 · DOI · Paper page
  25. Obregon, 2006, ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein, J Biol Chem., 281, 16419, 10.1074/jbc.M600617200 · DOI · Paper page
  26. Etcheberrigaray, 2004, Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice, Proc Natl Acad Sci U S A., 101, 11141, 10.1073/pnas.0403921101 · DOI · Paper page
  27. Holthoewer, 2012, Acitretin an enhancer of alpha-secretase expression, crosses the blood-brain barrier and is not eliminated by P-glycoprotein, Neurodegener Dis., 10, 224, 10.1159/000334300 · DOI
  28. Tippmann, 2009, Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin, FASEB J., 23, 1643, 10.1096/fj.08-121392 · DOI · Paper page
  29. Endres, 2014, Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin, Neurology., 83, 1930, 10.1212/WNL.0000000000001017 · DOI · Paper page
  30. Gauthier, 2009, Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: Exploratory analyses of the MRI sub-group of the Alphase study, J Nutr Health Aging., 13, 550, 10.1007/s12603-009-0106-x · DOI · Paper page
  31. Bilikiewicz, 2004, Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease, J Alzheimers Dis., 6, 17, 10.3233/JAD-2004-6103 · DOI · Paper page
  32. Aytan, 2013, Combination therapy in a transgenic model of Alzheimer's disease, Exp Neurol., 250, 228, 10.1016/j.expneurol.2013.10.001 · DOI · Paper page
  33. Matlack, 2014, Clioquinol promotes the degradation of metal-dependent amyloid-β (Aβ) oligomers to restore endocytosis and ameliorate Aβ toxicity, Proc Natl Acad Sci U S A., 111, 4013, 10.1073/pnas.1402228111 · DOI · Paper page
  34. Nalivaeva, 2008, Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease, Curr Alzheimer Res., 5, 212, 10.2174/156720508783954785 · DOI · Paper page
  35. Higuchi, 2005, Understanding molecular mechanisms of proteolysis in Alzheimer's disease: Progress toward therapeutic interventions, Biochim Biophys Acta., 1751, 60, 10.1016/j.bbapap.2005.02.013 · DOI
  36. Deane, 2012, Is RAGE still a therapeutic target for Alzheimer's disease?, Future Med Chem., 4, 915, 10.4155/fmc.12.51 · DOI · Paper page
  37. Deane, 2008, The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease, Curr Pharm Des., 14, 1601, 10.2174/138161208784705487 · DOI · Paper page
  38. Bates, 2009, Clearance mechanisms of Alzheimer's amyloid-beta peptide: Implications for therapeutic design and diagnostic tests, Mol Psychiatry., 14, 469, 10.1038/mp.2008.96 · DOI · Paper page
  39. Galasko, 2014, Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease, Neurology., 82, 1536, 10.1212/WNL.0000000000000364 · DOI · Paper page
  40. Wiessner, 2011, The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects, J Neurosci., 31, 9323, 10.1523/JNEUROSCI.0293-11.2011 · DOI · Paper page
  41. Muhs, 2007, Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice, Proc Natl Acad Sci U S A, 104, 9810, 10.1073/pnas.0703137104 · DOI · Paper page
  42. Liu, 2013, MER5101, a novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PS1ΔE9 transgenic mice, J Neurosci., 33, 7027, 10.1523/JNEUROSCI.5924-12.2013 · DOI · Paper page
  43. Panza, 2014, Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: The point of no return, Expert Opin Biol Ther, 14, 1465, 10.1517/14712598.2014.935332 · DOI · Paper page
  44. Panza, 2014, Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: The way forward, Expert Rev Clin Immunol., 10, 405, 10.1586/1744666X.2014.883921 · DOI · Paper page
  45. Novakovic, 2013, Profile of gantenerumab and its potential in the treatment of Alzheimer's disease, Drug Des Devel Ther., 7, 1359
  46. Jacobsen, 2014, Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APP London mice, J Neurosci., 34, 11621, 10.1523/JNEUROSCI.1405-14.2014 · DOI · Paper page
  47. Jindal, 2014, Alzheimer disease immunotherapeutics: Then and now, Hum Vaccin Immunother., 10, 2741, 10.4161/21645515.2014.970959 · DOI · Paper page
  48. Dodel, 2013, Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: A phase 2, randomised, double-blind, placebo-controlled, dose-finding trial, Lancet Neurol., 12, 233, 10.1016/S1474-4422(13)70014-0 · DOI · Paper page
  49. Relkin, 2009, 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease, Neurobiol Aging., 30, 1728, 10.1016/j.neurobiolaging.2007.12.021 · DOI · Paper page
  50. Szabo, 2010, Measurement of anti-beta amyloid antibodies in human blood, J Neuroimmunol., 227, 167, 10.1016/j.jneuroim.2010.06.010 · DOI

Cited by

See all 97

Metadata

Authors
Folch, J., Ettcheto, M., Petrov, D., Abad, S., Pedrós, I., Marin, M., Olloquequi, J., & Camins, A.
Venue
Neurología
Publisher
Elsevier BV
Published
2018-01
Volume
33
Issue
1
Pages
47-58
ISSN
0213-4853 (ISSN-L)
OpenAlex
W2608752954
Cited by
97
References
18
FWCI
1.29
Type
journal article
Language
es
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.